Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, January 11, 2021
[ Mon, Jan 11th 2021
] - WOPRAI
[ Mon, Jan 11th 2021
] - WOPRAI
[ Mon, Jan 11th 2021
] - WOPRAI
[ Mon, Jan 11th 2021
] - WOPRAI
[ Mon, Jan 11th 2021
] - WOPRAI
[ Mon, Jan 11th 2021
] - WOPRAI
[ Mon, Jan 11th 2021
] - WOPRAI
[ Mon, Jan 11th 2021
] - WOPRAI
[ Mon, Jan 11th 2021
] - WOPRAI
Sun, January 10, 2021
[ Sun, Jan 10th 2021
] - WOPRAI
[ Sun, Jan 10th 2021
] - WOPRAI
[ Sun, Jan 10th 2021
] - WOPRAI
Fri, January 8, 2021
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
[ Fri, Jan 08th 2021
] - WOPRAI
Matthew Harrison Downgraded (SRPT) to Hold and Decreased Target to $95 on, Jan 8th, 2021
Matthew Harrison of Morgan Stanley, Downgraded "Sarepta Therapeutics, Inc." (SRPT) to Hold and Decreased Target from $182 to $95 on, Jan 8th, 2021.
Matthew has made no other calls on SRPT in the last 4 months.
There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Matthew
- Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $212 on, Wednesday, October 28th, 2020
- Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $190 on, Tuesday, September 15th, 2020
